VFA
MACK

Valeo Financial Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Valeo Financial Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,000
Closed -$40K – 1789
2019
Q3 		$40K Sell
9,000
-2,439
-21% -$12.2K ﹤0.01% 677
2019
Q2 		$54K Hold
11,439
– – 0.01% 574
2019
Q1 		$63K Hold
11,439
– – 0.01% 516
2018
Q4 		$35K Hold
11,439
– – ﹤0.01% 587
2018
Q3 		$35K Buy
+11,439
New +$48.2K ﹤0.01% 629

Other funds holding MACK

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Valeo Financial Advisors's MACK Position: Q4 2019 in Review

Valeo Financial Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2019, closing a stake of 9,000 shares — an estimated $40K sold.

Valeo Financial Advisors first reported a position in MACK in Q3 2018 and held it in 5 quarters. The position peaked at $63K in Q1 2019. 48 funds tracked by Wall St. Rank hold MACK as of Q4 2019.

  • Valeo Financial Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Valeo Financial Advisors sold 9,000 Merrimack Pharmaceuticals, Inc. shares in Q4 2019, an estimated $40K.
  • Valeo Financial Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2018 and held it in 5 quarters.
  • Valeo Financial Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $63K in Q1 2019.
  • 48 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2019.

Based on Valeo Financial Advisors's 13F filing for Q4 2019, filed 24 Jan 2020.